SCHEMBL21756535

SCHEMBL21756535

Cc1cc(F)cc([N+](=O)[O-])c1NC(=O)CCl

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 0.44
HPGD P15428 3/20 0.44
GAA P10253 2/20 0.44
LMNA P02545 8/20 0.44
SMN1; SMN2 Q16637 6/20 0.44
NPC1 O15118 1/20 0.44
MAPT P10636 6/20 0.42
TDP1 Q9NUW8 4/20 0.42
L3MBTL1 Q9Y468 4/20 0.42
MAPK1 P28482 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
PKM P14618 1/20 0.40
HTT P42858 2/20 0.39
RECQL P46063 1/20 0.38
POLB P06746 1/20 0.38
MITF O75030 1/20 0.38
XBP1 P17861 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29722774 0.82 ALDH1A1 (0.48) ALDH1A1HPGDGAALMNASMN1; SMN2
SCHEMBL3300905 0.82 ALDH1A1 (0.48) ALDH1A1HPGDGAALMNASMN1; SMN2
SCHEMBL11650801 0.78 ALDH1A1 (0.52) ALDH1A1HPGDLMNASMN1; SMN2NPC1
SCHEMBL11227724 0.77 KCNMA1 (0.58) ALDH1A1LMNASMN1; SMN2NPC1TDP1
SCHEMBL2821496 0.75 LMNA (0.43) ALDH1A1HPGDLMNASMN1; SMN2NPC1
SCHEMBL11666580 0.74 ALDH1A1 (0.50) ALDH1A1HPGDLMNASMN1; SMN2NPC1
SCHEMBL29064908 0.74 RECQL (0.63) ALDH1A1LMNASMN1; SMN2MAPTTDP1
SCHEMBL14203410 0.72 TSHR (0.47) ALDH1A1HPGDSMN1; SMN2MAPTTDP1
SCHEMBL11525238 0.71 ALDH1A1 (0.59) ALDH1A1HPGDGAALMNASMN1; SMN2
SCHEMBL2205099 0.71 RAB9A (0.63) ALDH1A1HPGDLMNASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2021-05-18 US disclosed
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) 2020-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008292-B2 FGFR4 inhibitor and preparation method and use thereof FGFR4, FGFR1, FGFR2 ALDH1A1 993/4885HPGD 3462/4885GAA 768/4885
US-20200062716-A1 FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF FGFR4, FGFR1, FGFR2 ALDH1A1 993/4885HPGD 3462/4885GAA 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.